These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Should recombinant human growth hormone therapy be used in short small for gestational age children?
    Author: Johnston LB, Savage MO.
    Journal: Arch Dis Child; 2004 Aug; 89(8):740-4. PubMed ID: 15269075.
    Abstract:
    Short small for gestational age (SGA) children represent 20% of all children with short stature and therefore constitute a significant portion of the caseload in a growth clinic. The recent approval of recombinant human growth hormone (GH) for the treatment of short stature in SGA children by the European Union's Committee on Proprietary Medicinal Products offers a new licensed therapeutic option. This article examines the role of GH therapy in short SGA children with particular reference to selection of patients, effectiveness, safety, and its potential metabolic implications.
    [Abstract] [Full Text] [Related] [New Search]